Overview

Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 827

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Bausch Health Americas, Inc.